Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation

نویسندگان

  • Vittorio Pengo
  • Luciano Crippa
  • Anna Falanga
  • Guido Finazzi
  • Francesco Marongiu
  • Gualtiero Palareti
  • Daniela Poli
  • Sophie Testa
  • Eros Tiraferri
  • Alberto Tosetto
  • Armando Tripodi
  • Cesare Manotti
چکیده

Vittorio Pengo1; Luciano Crippa2; Anna Falanga3; Guido Finazzi4; Francesco Marongiu5; Gualtiero Palareti6; Daniela Poli7; Sophie Testa8; Eros Tiraferri9; Alberto Tosetto10; Armando Tripodi11; Cesare Manotti12 1Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy; 2Thrombosis Research Unit, IRCCS H S.Raffaele, Milan, Italy; 3Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy; 4Division of Hematology, Ospedali Riuniti, Bergamo, Italy; 5Department of Medical Sciences, University Hospital, Cagliari, Italy; 6Department of Angiology and Blood Coagulation ′′Marino Golinelli′′, University Hospital, Bologna, Italy; 7Department of Heart and Vessels, Thrombosis Center, Careggi University Hospital, Firenze, Italy; 8Thrombosis Centre, District Hospital, Cremona, Italy; 9Haemostasis and Thrombosis Centre, City Hospital, Rimini, Italy; 10Department of Hematology, San Bortolo Hospital, Vicenza, Italy; 11Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milan, Italy; 12 Anticoagulation Service, Fidenza, Italy

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin

  Atrial fibrillation (AF) is associated with inflammatory and hypercoagulability state. Previous studies evaluated the safety and efficacy of dabigatran and warfarin in prevention of thrombothic complications. This study was intended to assess the influence of these drugs on hemostatic and inflammatory markers among patient underwent pulmonary vein ablation.   A total of 100 patients with AF w...

متن کامل

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin

  Atrial fibrillation (AF) is associated with inflammatory and hypercoagulability state. Previous studies evaluated the safety and efficacy of dabigatran and warfarin in prevention of thrombothic complications. This study was intended to assess the influence of these drugs on hemostatic and inflammatory markers among patient underwent pulmonary vein ablation.   A total of 100 patients with AF w...

متن کامل

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions

Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the join...

متن کامل

The Prevalence of Prescription of New Anticoagulant Drugs and Its Determinant Factors in Patients With Ischemic Stroke and Non-valvular Atrial Fibrillation

Background: Patients with ischemic stroke and underlying Atrial Fibrillation (AF) have a high risk of recurrent embolic events. New Oral Anticoagulant (NOAC) is highly effective and reduces the risk of recurrence in AF-associated Ischemic Stroke (AFAIS). Objectives: This study aimed to determine the prescription pattern of NOAC and its determinant factors in patients with non-valvular AFAIS. ...

متن کامل

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness

Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown to decrease the incidence of cardioembolic stroke in patients with AF by more than 50%. Appropriate use of anticoagulation with vitamin K antagonists requires precise adherence and monitoring. A number of factors tha...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011